Literature DB >> 1840703

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

P van der Bruggen1, C Traversari, P Chomez, C Lurquin, E De Plaen, B Van den Eynde, A Knuth, T Boon.   

Abstract

Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line. This gene shows no similarity to known sequences and belongs to a family of at least three genes. It is expressed by the original melanoma cells, other melanoma cell lines, and by some tumor cells of other histological types. No expression was observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the gene. Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1840703     DOI: 10.1126/science.1840703

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  809 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  How much help does a vaccine-induced T-cell response need?

Authors:  J S Weber; J J Mulé
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

4.  Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.

Authors:  K Lee; W W Overwijk; M O'Toole; H Swiniarski; N P Restifo; A J Dorner; S F Wolf; K Sturmhoefel
Journal:  J Interferon Cytokine Res       Date:  2000-06       Impact factor: 2.607

Review 5.  Benign autoimmunity to combat malignancy.

Authors:  H J Stauss
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

Review 6.  Regulatory role of CD4+ T cells during the development of contact hypersensitivity responses.

Authors:  A V Gorbachev; R L Fairchild
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 7.  Immunotherapy of melanoma.

Authors:  C Smith; V Cerundolo
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

8.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

9.  Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene.

Authors:  Liyan Lin; Juanbing Wei; Yuqing Chen; Aimin Huang; Kay Ka-Wai Li; Wenmin Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

Review 10.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.